Skip to main content

GoPath Labs to Commercialize IntegraGen Cancer Therapy Biomarker Test

NEW YORK (GenomeWeb) – IntegraGen and GoPath Laboratories said today that they have signed a non-exclusive licensing agreement under which GoPath plans to commercialize a test based on IntegraGen's proprietary miR-31-3p biomarker in the US and Canada.

IntegraGen has already made an miR-31-3p kit available as a CE-IVD-marked test in Europe. It's designed to help clinicians identify metastatic colorectal cancer patients who have a higher likelihood of response to anti-EGFR therapy.

"Based on published clinical data which demonstrates the ability of miR-31-3p to proactively identify RAS wild-type metastatic colorectal cancer patients who will have increased benefit from treatment with anti-EGFR therapy, we feel the miR-31-3p expression test will complement our existing test offering for this patient population," GoPath Founder and CEO Jim Lu said in a statement.

Lu added that the company is planning to make the test available to clinicians within the year, after completing validation steps in its Illinois laboratory.

Financial terms of the deal were not disclosed.